HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Regulus Therapeutics (NASDAQ:RGLS) and maintained a $9 price target.
March 25, 2024 | 10:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirmed a Buy rating on Regulus Therapeutics with a $9 price target.
The reiteration of a Buy rating and maintenance of a $9 price target by a reputable analyst firm like HC Wainwright & Co. could instill confidence among investors and potentially lead to a positive short-term impact on RGLS's stock price. Analyst ratings often influence investor perception and can lead to price movements.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100